Press release
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1
About this update from Cytomx Therapeutics, Inc.
[{"type":"text","content":"- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) in melanoma - - Company to host conference call today at 5 p.m. EST / 2 p.m. PST - SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced third quarter 2025 financial results and provided a business update. “CytomX continued to execute against its pipeline priorities this quarter, highlighted by robust Phase 1 expansion enrollment for CX-2051. We remain on track for a CX-2051 Phase 1 data update in Q1 2026. Looking ahead to 2026, CX-2051 is well positioned as a first-in-class EpCAM-directed, topoisomerase-1 ADC designed to address the high unmet need in CRC and a wide range of other EpCAM-expressing indications. CytomX’s top priority is to advance CX-2051 towards a potential registrational study in advanced, late-line CRC. Additionally, we continue to plan for focused investments to further unlock the potential of CX-2051, including moving into earlier lines of CRC therapy and additional EpCAM positive cancers,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. Dr. McCarthy continued “We are also pleased with the dose escalation progress for our PROBODY® interferon alpha-2b, CX-801, and look forward to presenting encouraging initial biomarker data at SITC which underscore this potent masked cytokine’s therapeutic potential in combination with checkpoint inhibitors in advanced melanoma.” Q3 2025 Pipeline Program Updates: CX-2051 (EpCAM PROBODY Topo-1 ADC) CX-2051 Phase 1 dose expansions across the 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses, administered every three weeks (Q3W) are ongoing.In Q3 2025, dose expansion enrollment continued with the goal of supporting a potential registrational study of CX-2051 monotherapy in advanced CRC.Phase 1 study enrollment is projected to reach approximately 100 patients by the planned CX-2051 Phase 1 update in Q1 2026.A Phase 1b CX-2051 combination study with bevacizumab in CRC is expected to start in Q1 2026, data from which is intended to inform potential late-ph...